Oruka Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
ORKA$104.56+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report are set forth below.
| EXHIBIT NUMBER | DESCRIPTION | FORM | EXHIBIT | FILING DATE |
|---|---|---|---|---|
| 2.1† | Agreement and Plan of Merger and Reorganization, dated as of April 3, 2024, by and among ARCA biopharma, Inc., Atlas Merger Sub Corp., Atlas Merger Sub II, LLC and Oruka Therapeutics, Inc. | 8-K | 2.1 | April 3, 2024 |
| 3.1 | Second Amended and Restated Certificate of Incorporation of the Company, filed September 3, 2024. | 8-K | 3.5 | September 5, 2024 |
| 3.2 | Amended and Restated Bylaws of the Company. | 8-K | 3.6 | September 5, 2024 |
| 3.4 | Form of Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock. | S-1/A | 3.1(b) | May 24, 2013 |
| 3.5 | Certificate of Elimination of Series A Convertible Preferred Stock, effective August 29, 2024. | 8-K | 3.8 | September 5, 2024 |
| 3.6 | Certificate of Designation of Preferences, Rights and Limitations of Series B Non-Voting Convertible Preferred Stock. | 8-K | 3.9 | September 5, 2024 |
| 3.7 | Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock. | 8-K | 3.1 | September 13, 2024 |
| 4.1 | Description of Securities. | 10-K | 4.1 | March 6, 2025 |
| 4.2 | Investor Rights Agreement, dated March 6, 2024, by and among Oruka Therapeutics, Inc. and certain parties thereto. | S-4 | 4.3 | May 14, 2024 |
| 4.3 | Form of Pre-Funded Warrant, dated August 29, 2024. | 10-K | 4.3 | March 6, 2025 |
| 4.4 | Form of Pre-Funded Warrant, dated September 13, 2024. | 8-K | 4.1 | September 13, 2024 |
| 4.5* | Paruka Warrant, dated December 31, 2024 | |||
| 10.1† | IL-17 License Agreement by and between Paragon Therapeutics, Inc. and Oruka Therapeutics, Inc., dated February 4, 2025. | 10-K | 10.29 | March 6, 2025 |
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) promulgated under the Securities Exchange Act of 1934 | |||
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) promulgated under the Securities Exchange Act of 1934 | |||
| 32.1** | Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(B) promulgated under the Securities Exchange Act of 1934 | |||
| 101.INS | Inline XBRL Instance Document | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema with Embedded Linkbases Document | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||
| * | Filed herewith. |
| ** | Furnished herewith. The certifications on Exhibit 32.1 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. |
| # | Indicates management contract or compensatory plan. |
| † | Exhibits and/or schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company hereby undertakes to furnish supplementally copies of any of the omitted exhibits and schedules upon request by the SEC; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished. Certain portions of this exhibit (indicated by “[***]”) have been omitted because they are both (i) not material and (ii) is the type of information that the registrant both customarily and actually treats as private and confidential. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.